Listen to the article
Federal authorities announced Monday that an Indianapolis-based laboratory has been ordered to pay more than $9 million to resolve allegations that it violated both the False Claims Act and Anti-Kickback Statute through improper billing practices.
Genesis Reference Laboratories, headquartered in Indianapolis, agreed to the settlement after investigators determined the company submitted claims to Medicare for unnecessary genetic testing and engaged in financial arrangements that violated federal anti-kickback laws.
According to the U.S. Department of Justice, Genesis was accused of paying kickbacks to marketers who then recruited Medicare beneficiaries to undergo genetic testing, regardless of medical necessity. The company allegedly disguised these payments as legitimate marketing expenses to circumvent federal healthcare regulations.
“Laboratories that engage in kickback schemes undermine the integrity of our healthcare system,” said U.S. Attorney Zachary A. Myers for the Southern District of Indiana. “When medical decisions are influenced by financial incentives rather than patient needs, it not only violates public trust but also wastes valuable healthcare resources.”
The investigation revealed that between January 2018 and December 2021, Genesis routinely billed Medicare for expensive genetic tests that were not ordered by physicians who were treating the patients. In many cases, the tests had no clinical value for the beneficiaries involved.
Medicare regulations specifically require that genetic testing be ordered by a treating physician based on medical necessity and appropriate diagnostic criteria. The government alleges Genesis circumvented these requirements by using telemarketers who contacted Medicare beneficiaries directly, often persuading elderly patients to provide cheek swabs for testing.
The settlement of $9,125,000 represents one of the largest healthcare fraud recoveries in Indiana in recent years. Under the terms of the agreement, Genesis did not admit liability but agreed to implement a comprehensive compliance program to prevent similar violations in the future.
The case highlights growing concerns about fraud in the genetic testing industry, which has expanded rapidly as testing technology has become more accessible and Medicare coverage for certain genetic tests has increased. The Centers for Medicare and Medicaid Services (CMS) has identified genetic testing fraud as a priority area for enforcement.
“The healthcare fraud schemes we’re seeing in genetic testing are increasingly sophisticated,” said Mario Pinto, Special Agent in Charge with the Department of Health and Human Services Office of Inspector General. “Companies are finding creative ways to disguise kickbacks and manipulate the system. This settlement sends a strong message that such behavior will not be tolerated.”
Healthcare fraud experts note that improper genetic testing schemes often target vulnerable populations, particularly seniors, through telemarketing calls, health fairs, or even door-to-door solicitation. The tests, which can cost Medicare thousands of dollars each, frequently provide little clinical benefit to patients while generating substantial profits for laboratories.
The Genesis case was brought to light through whistleblower provisions of the False Claims Act, which allow private citizens with knowledge of fraud to file lawsuits on behalf of the government and share in any recovery. The identity of the whistleblower in this case remains confidential.
As part of the settlement, Genesis will enter into a corporate integrity agreement with federal health authorities that requires regular compliance reporting and independent monitoring of billing practices for the next five years.
This case is part of a broader national enforcement effort targeting healthcare fraud. In 2022 alone, the Justice Department recovered more than $2.2 billion from False Claims Act cases, with a significant portion coming from healthcare fraud matters.
Indiana health officials have advised Medicare beneficiaries to be vigilant about genetic testing offers and to consult with their primary care physicians before agreeing to any genetic tests. Patients should be wary of testing that is marketed as “free to you” or advertised with claims that Medicare will cover the cost completely.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
7 Comments
Genetic testing should be guided by medical necessity, not financial incentives. This case highlights the importance of strong regulations and enforcement to prevent abuse of government healthcare programs.
Absolutely. Patients need to be able to trust that their healthcare providers are acting in their best interests, not their own financial interests. This was a clear violation of that trust.
This is a concerning case of a lab allegedly taking advantage of the healthcare system through improper billing practices and kickbacks. It’s good to see the authorities taking action to hold them accountable and protect patients and taxpayers.
Agreed, the details on how they disguised the kickbacks as marketing expenses is particularly troubling. Oversight and enforcement are crucial to maintain integrity in the healthcare industry.
The lab’s alleged actions seem egregious, using kickbacks to recruit patients for unnecessary testing. I’m glad the authorities were able to uncover this and hold the company accountable through substantial fines.
This is a good example of the government taking appropriate action to protect taxpayer funds and patient wellbeing. I hope the penalties and enforcement efforts continue to root out any similar issues in the healthcare industry.
Over $9 million in penalties is a significant amount. It sends a strong message that this kind of fraudulent behavior will not be tolerated. Hopefully it serves as a deterrent to other labs considering similar practices.